Dual rate-dependent cardiac electrophysiologic effects of haloperidol: Slowing of intraventricular conduction and lengthening of repolarization

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 6, 2003, Pages 870-879

  Mörtl, Deddo ^a   Agneter, Ernst ^a   Krivanek, Peter ^a   Koppatz, Karl ^a   Todt, Hannes ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Conduction; Droperidol; Haloperidol; Long QT; Repolarization

Indexed keywords

DROPERIDOL; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; EXPERIMENTAL MODEL; GUINEA PIG; HEART ARRHYTHMIA; HEART ATRIUM PACING; HEART CYCLE; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART REPOLARIZATION; HEART STIMULATION; HEART VENTRICLE CONDUCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; TIME SERIES ANALYSIS;

EID: 0037780747     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200306000-00007     Document Type: Article

References (70)

1. Hansen-Flaschen JH, Brazinsky S, Basile C, et al. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey. JAMA. 1991;266:2870-5.
2. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Society of Critical Care Medicine. Crit Care Med. 1995; 23:1596-600.
3. Mehta D, Mehta S, Petit J, et al. Cardiac arrhythmias and haloperidol. Am J Psychiatry. 1979;136:1468-9.
4. Zee-Cheng CS, Mueller CE, Seifert CF, et al. Haloperidol and torsades de pointes. Ann Int Med. 1985;102:418.
5. Huyse F, van Schijndel RS. Haloperidol and cardiac arrest. Lancet. 1988;2(8610)568-9.
6. Aunsholt NA. Prolonged Q-T interval and hypokalemia caused by haloperidol. Acta Psychiatr Scand. 1989;79:411-2.
7. Levine BS, Wu SC, Goldberger BA, et al. Two fatalities involving haloperidol. J Anal Toxicol. 1991;15:282-4.
8. T and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol. 1993;13:128-32.
9. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann. Pharmacother. 1999;33:1046-50.
10. Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med. 1993;119:391-4.
11. Di Salvo TG, O'Gara PT. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol. 1995;18:285-90.
12. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med. 1997;157:2013-5.
13. T interval. J Clin Psychopharmacol. 2001;21:257-61.
14. Ogata N, Narahashi T. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br J Pharmacol. 1989;97:905-13.
15. Suessbrich H, Schonherr R, Heinemann SH, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997;120:968-74.
16. Han J, Moe GK. Nonuniform recovery of excitability in ventricular muscle. Circ Res. 1964;14:44-60.
17. Levine JH, Morganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Circulation. 1989;80:1063-69.
18. T prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-33.
19. Varro A, Lathrop DA. Sotalol and mexiletine: combination of rate-dependent electrophysiological effects. J Cardiovasc Pharmacol. 1990; 16:557-67.
20. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation. 1997;96:2038-47.
21. Todt H, Zojer N, Djamshidian-Tehrani S, et al. Frequency-dependent effects of amitriptyline and maprotiline on conduction in the guinea pig His-Purkinje-system in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:670-6.
22. Todt H, Zojer N, Raberger G. Kinetics of rate-dependent slowing of intraventricular conduction by the class Ib antiarrhythmic agent tocainide in vivo. Br J Pharmacol. 1993;110:145-50.
23. Todt H, Zojer N, Raberger G. Dynamics of mexiletine induced rate-dependent HV prolongation during co-administration of the novel class III antiarrhythmic agent dofetilide [abstract]. Resuscitation. 1993;25:93.
24. T interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction. Eur J Pharmacol. 1994;265:43-52.
25. + current by dofetilide. Circ Res. 1993;72:75-83.
26. Turgeon J, Wisialowski TA, Wong W, et al. Suppression of longitudinal versus transverse conduction by sodium channel block: effects of sodium bolus. Circulation. 1992;85:2221-6.
27. Todt H, Raberger G. Epicardial His bundle recordings in the guinea pig in vivo. J Pharmacol Methods. 1992;27:191-5.
28. Steinhaus BM. Estimating cardiac transmembrane activation and recovery times from unipolar and bipolar extracellular electrograms: a simulation study. Circ Res. 1989;64:449-62.
29. T correction for heart rate: Implications for the detection of inhomogeneous repolarization after myocardial infarction. Am Heart J. 1992;124:602-9.
30. Williams DO, Scherlag BJ, Hope DR, et al. Selective versus non-selective His bundle pacing. Cardiovasc Res. 1976;10:91-100.
31. Franz MR, Swerdlow CD, Liem LB, et al. Cycle length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden rate acceleration and deceleration, and different steady state frequencies. J Clin Invest. 1988;82:972-9.
32. T interval to heart rate changes in isolated perfused guinea pig heart: influence of amiodarone and D-sotalol. Pharmacol Res. 1997;35:409-16.
33. Sukenobu I, Surawicz B. Effect of tetraethylammonium chloride on action potential in cardiac Purkinje fibers. Am J Physiol. 1981;241: H139-44.
34. Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987;1:365-78.
35. Gettes LS, Reuter H. Slow recovery from inactivation of inward currents in mammalian myocardial fibers. J Physiol. 1974;240:703-24.
36. max of ventricular action potentials. J Mol Cell Cardiol. 1985;14: 495-503.
37. Bean BP, Cohen CJ, Tsien RW. Lidocaine block ofcardiac sodium channels. J Gen Physiol. 1983;81:613-42.
38. Sanchez-Chapula J, Tsuda Y, Josephson IR. Voltage- and use-dependent effects of lidocaine on sodium current in rat single ventricular cells. Circ Res. 1983;52:557-65.
39. Clarkson CW, Hondeghem LM. Evidence for a specific receptor site for lidocaine, quinidine, and bupivacaine associated with cardiac sodium channels in guinea pig ventricular myocardium. Circ Res. 1985;56: 496-506.
40. Lathrop DA, Varró A. The combined electrophysiological effects of lignocaine and sotalol in canine isolated cardiac Purkinje fibres are rate-dependent. Br J Pharmacol. 1990;99:124-30.
41. T interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol. 1998; 18:477-81.
42. T prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. Jpn Circ J. 2000; 64:445-51.
43. Sugiyama A, Satoh Y, Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appi Pharmacol. 2001;173:120-8.
44. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.
45. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806-17.
46. Tan AT, Ee BK, Chia BL. Torsade de pontes and complete heart block in familial cardiomyopathy. Singapore Med J 1984;25:84-6.
47. Adamantidis MM, Kerram P, Caron JF, et al. Droperidol exerts dual effects on repolarization and induces early afterdepolarizations and triggered activity in rabbit Purkinje fibers. J Pharmacol Exp Ther. 1993;266: 884-93.
48. Medlin RP Jr, Ransom MM, Watts JA, et al. Effect of ethanol, haloperidol, and lorazepam on cardiac conduction and contraction. J Cardiovasc Pharmacol. 1996;28:792-8.
49. Todt H, Zojer N, Djamshidian S, et al. Comparison of rate-dependent slowing of conduction within the His-Purkinje system by amitriptyline and maprotiline in vivo [abstract]. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:R52.
50. Packer DL, Grant AO, Strauss HC, et al. Characterization of concentration- and use-dependent effects of quinidine from conduction delay and declining conduction velocity in canine Purkinje fibers. J Clin Invest. 1989;83:2109-19.
51. Villemaire C, Savard P, Talajic M, et al. A quantitative analysis of use-dependent ventricular conduction slowing by procainamide in anesthetized dogs. Circulation. 1992;85:2255-66.
52. Beam KG, Donaldson PL. A quantitative study of potassium channel kinetics in rat skeletal muscle from 1 to 37°C. J Gen Physiol. 1983;81: 485-512.
53. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit. Circulation. 1991;84:1831-51.
54. Tisdale JE, Kambe JC, Chow MS, et al. The effect of haloperidol on ventricular fibrillation threshold in pigs. Pharmacol Toxicol. 1991;69:327-9.
55. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994;22:433-40.
56. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy. 1997;17:531-7.
57. Starmer CF, Lancester AR, Lastra AA, et al. Cardiac instability amplified by use-dependent Na channel blockade. Am J Physiol. 1992;262: H1305-10.
58. Starmer CF, Lastra AA, Nesterenko VV, et al. Proarrhythmic response to sodium channel blockade: theoretical model and numerical experiments. Circulation. 1991;84:1364-77.
59. Todt H, Zojer N, Schütz W. Rate-dependent slowing of intraventricular conduction by amitriptyline and by maprotiline in vivo. J Mol Cell Cardiol. 1994;26:LXXII.
60. Holley FO, Magliozzi JR, Stanski DR, et al. Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther. 1983;33:477-84.
61. Odou P, Vaiva G, Luyckx M, et al. Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol. Eur J Clin Pharmacol. 1996;50:357-63.
62. Dudley DL, Rowlett DB, Loebel PJ. Emergency use of intravenous haloperidol. Gen Hosp Psychiatry. 1979;1:240-6.
63. Tesar GE, Murray GB, Cassem NH. Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. J Clin Psychopharmacol. 1985;5:344-7.
64. Tesar GE, Stern TA. Rapid tranquilization of the agitated intensive care unit patient. J Intensive Care Med. 1988;3:195-201.
65. Sanders KM, Murray GB, Cassem NH. High-dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aortic balloon pump. J Clin Psychopharmacol. 1991;11:146-7.
66. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother. 1995;29:690-3.
67. Korpi ER, Kleinman JE, Costakos DT, et al. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res. 1984; 11:259-69.
68. Johnson GR. High haloperidol concentrations in a traffic suicide. J Forensic Sci. 1988;33:823-5.
69. Wang Z, Pelletier LC, Talajic M, et al. Effects of flecainide and quinidine on human atrial action potentials: role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation. 1990;82:274-83.
70. Lu HR, Marien R, Saels A, et al. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol. 2001;12: 93-102.